Lineage Cell Therapeutics, Inc. LCTX

Rising rates are squeezing indebted businesses. Meet three small cap stocks with strong revenue growth and low debt, plus a screener to find more like them.

CARLSBAD, Calif., September 08, 2026--AlloSCOPE 5D Patent Release

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and hearing loss programs while Roche and Genentech continue surgical-delivery optimiza

Moby summary of Lineage Cell Therapeutics, Inc.'s Q2 2026 earnings call

Lineage Cell Therapeutics Inc (LCTX) reports net income of $1.5 million, extends cash runway into Q3 2028, and advances key pipeline programs despite revenue decline.

CARLSBAD, Calif., August 06, 2026--Q2 2026 Earnings Release

CARLSBAD, Calif., July 30, 2026--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, "off the shelf", cell therapies for serious medical conditions, today announced that it will report its second quarter 2026 financial and operating results on August 6, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on August 6, 2026, at 4:30 p.m. Eastern Time

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) used a conference call to outline its manufacturing strategy and development plans for COR1, a wholly owned preclinical cell transplant program being developed as a potential treatment for corneal endothelial disease. Chief Executive Officer Brian Culle

CARLSBAD, Calif., July 13, 2026--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, "off the shelf", cell therapies for serious medical conditions, today provided an update on COR1, the Company’s allogeneic corneal endothelial cell (CEnC) transplant program, in preclinical development for the treatment of corneal endothelial disease. With COR1, Lineage is deploying its ophthalmology and cell manufacturing expertise

CARLSBAD, Calif., July 06, 2026--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing "off the shelf" allogeneic cell therapies for serious medical conditions, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit, in a fireside chat hosted by Mayank Mamtani, Senior Managing Director, Group Head of Healthcare Research and Senio

The updated analyst narrative around Lineage Cell Therapeutics centers on a reaffirmed US$5.50 price target, with recent research focusing on how this level lines up with the company’s current execution profile. Rather than introducing new drivers, analysts are assessing whether Lineage can deliver against the assumptions already embedded in their valuation work and how closely the stock might track that US$5.50 reference point. As you read on, you will see how this evolving story, including...

Lineage Cell Therapeutics is back on investor radar as bullish analysts lift their price target from US$4.50 to US$5.50 per share, pointing to a different view on where the stock could sit if their models play out. These higher targets are being framed as better aligned with updated assumptions on revenue potential and earnings power. At the same time, more cautious voices still point to execution risk and the gap between current fundamentals and those projections. As you read on, you will...

The United States market has shown robust performance, with a 1.2% increase over the last week and a substantial 29% rise over the past year, alongside an optimistic forecast for earnings growth of 17% annually. In light of these conditions, investors might find opportunity in stocks that balance affordability with potential growth, particularly those often labeled as penny stocks. While the term may seem outdated, these smaller or newer companies can offer intriguing prospects when backed by...

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program in geographic atrophy, a newly launched corneal endothelial cell program called COR1, and ongoing ma

Moby summary of Lineage Cell Therapeutics, Inc.'s Q1 2026 earnings call

Lineage Cell Therapeutics Inc (LCTX) showcases promising program developments and a robust cash position, despite facing operational challenges and increased net loss.